Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience by Moslemi, Mohammad Kazem et al.
© 2011 Moslemi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Cancer Management and Research 2011:3 227–231
Cancer Management and Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
227
ORiginAL ReseARCh
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CMR.S18147
evaluation of prostate cancer prevalence  
in iranian male population with increased  
PsA level, a one center experience
Mohammad Kazem 
Moslemi1
Fariborz Lotfi2
seyed Ali Tahvildar3
1Department of Urology, Kamkar 
hospital, school of Medicine, Qom 
University of Medical sciences, Qom, 
iran; 2school of Medicine, Kermanshah 
University of Medical sciences, 
Kermanshah, iran; 3Department of 
Urology, school of Medicine, islamic 
Azad University, Qom Branch, Qom, iran
Correspondence: Fariborz Lotfi 
school of Medicine, Kermanshah 
University of Medical sciences, 
Kermanshah, 1494883113, iran 
Tel +98 912 197 7131 
email dr.f.lotfi@gmail.com
Purpose: This study was conducted to evaluate the incidence of prostate cancer (PCa) in Iranian 
male patients with increased prostate-specific antigen (PSA), and normal or abnormal digital 
rectal examination (DRE) that underwent prostate biopsy.
Materials and methods: From March 2006 to April 2009, a total of 346 consecutive males 
suspected of having PCa due to increased PSA levels underwent transrectal ultrasonography 
(TRUS)-guided sextant biopsy of the prostate. The total PSA (tPSA), demographic data, 
  incidence of PCa, benign prostate hyperplasia (BPH), and prostatitis were assessed.
Results: The patients were divided into two groups according to their PSA values (group A serum 
tPSA level, 4–10 ng/mL; group B serum tPSA level, 10.1–20.0 ng/mL). Of the 346 biopsied 
cases, 193 cases (56%) had PCa, 80 cases (23%) had BPH, and 73 cases (21%) had prostatitis. 
The mean PSA and the age of the carcinoma group were significantly higher than those of the 
benign group (P , 0.01). The biopsy results were grouped as PCa, BPH, and   prostatitis. Incidence 
of PCa for group A and group B cases were 115 cases (51%), and 78 cases (65%), respectively. 
In the case of PCa, BPH, and prostatitis, the mean PSAs were 10.02 ng/mL, 8.76 ng/mL, and 
8.41 ng/mL, respectively (P , 0.40).
Conclusion: TRUS-guided prostate biopsy and interpretation by a skilled team is highly 
recommended for early detection of PCa or its ruling-out. It seems that a PSA cutoff value of 
4 ng/mL may be applied to the Iranian population. Although the chance of PCa is high in the 
PSA levels of 4–10 ng/mL, the combination of some data, like age and prostate volume, can 
decrease the rate of unnecessary prostate biopsies. We recommend prostate biopsy when PSA 
and/or DRE is elevated in symptomatic patients with obstructive and/or irritative lower urinary 
tract symptoms (LUTS) such as dysuria, frequency, or nocturia. Due to the very high incidence 
of PCa in the patients with PSA greater than 10 ng/mL, TRUS-guided biopsy is indicated, 
whatever the findings on DRE and/or LUTS, since the PCa detection rate is high.
Keywords: prostate-specific antigen, benign prostate hyperplasia, BPH, prostate biopsy, prostate 
carcinoma, PCa, digital rectal examination, DRE, lower urinary tract symptoms, LUTS
Introduction
Prostate cancer (PCa) is one of the most common cancers in the male population and 
is the second leading cause of cancer death for men in the USA.1 It is a major cause 
of morbidity and mortality in Iran,2 yet there are few studies determining the relation 
between prostate-specific antigen (PSA) levels and the risk of PCa. The mortality of 
PCa on the basis of geographic area differs. In the Scandinavian area and southern 
Europe its prevalence is high, and in eastern Asia its prevalence is the least. Its 
prevalence is directly related to age. PSA and digital rectal examination (DRE) are Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Dovepress
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good screening tools of PCa. In this retrospective study, we 
evaluated PCa prevalence in Iranian male patients that were 
referred to our center for transrectal prostate biopsy due to 
increased PSA level.
Unfortunately, in Iran, most PCa is already   associated 
with nonorgan-confined disease or bone metastasis at 
  detection. Therefore, focusing research on methods of its 
early detection has developed.2
PSA is secreted by the epithelial cells lining the acini and 
the ducts of the prostate gland in both normal and malignant 
conditions.3,4 The serum levels of PSA are elevated in PCa 
and benign prostate hyperplasia (BPH).3,5,6 Prostate biopsy 
has been usually performed in clinical practice in cases 
with increased PSA levels. Although a serum PSA level of 
4.0 ng/mL is used as a cutoff point for PCa screening, it is 
relatively difficult to differentiate prostate adenocarcinoma 
from benign prostatic hyperplasia (BPH) in patients with 
gray-zone PSA levels (4–10 ng/mL).8–11
PCa early detection guidelines are mainly based on data 
from the USA and Europe and may not be relevant to other 
geographic areas or ethnic groups.12
This study was designed to evaluate the significance of 
total PSA (tPSA) in the PSA of 4–10 ng/mL and its   comparison 
with PSA levels of 10–20 ng/mL for discrimination between 
benign and malignant prostate disease in Iranian men.
Materials and methods
This is a retrospective study in which Iranian males with 
increased PSA levels (4 ng/dL) that referred to transrectal 
ultrasound (TRUS) prostate biopsy were evaluated. In this 
study, a total of 346 males with increased PSA values with 
or without positive DRE (4–20 ng/mL) were evaluated in 
the 3 consecutive years from March 2006 to April 2009. The 
mean age of these patients was 65.81 years, ranging from 45 
to 87 years, with standard deviation (SD) of 8.50. Of these, 
39 (11.3%) were ,55 years old, 68 (19.7%) were between 
56 and 60 years old, 136 (39.3%) were between 61 and 
70 years old, 52 (15%) were between 71 and 75 years old, 
and 51 (14.7%) were .76 years old (Table 1). This study was 
performed in Bistoon Uroradiology Private Clinic,   Tehran, 
Iran. Prior to DRE, tPSA were measured for all of these 
patients. None of them had current urinary tract infections, 
clinical prostatitis, and history of prior prostate surgery (tran-
surethral resection of the prostate or open prostatectomy). 
A sextant biopsy was performed from the apex and base of 
the right and left parasagittal planes of the prostate with 10 
core biopsies. If hypoechoic areas were noted on TRUS, 
a specimen was taken from each of these areas.
Demographic data including age, PSA level, prostate 
volume, and pathology result were evaluated. PSA was 
measured by using the Tandem-R assay. Prostate volume 
was calculated by using the following formula:
	Π /6 × L × W × H,  (1)
where L = length, W = width, and H = height. The patients 
were divided into two groups: group A, with PSA level 
between 4 and 10 ng/dL; and group B, with PSA level 
between 10 and 20 ng/dL. On the basis of prostate weight, 
the mean, median, SD, and variance was 56.48 cm3, 49 cm3, 
27.34, and 747.94, respectively.
The total number in group A was 226 (65.3%), and 
group B was 120 (34.7%) (Tables 2 and 3). One experienced 
pathologist performed the histopathological examinations. 
Atypical small acinar proliferation and prostate intraepithelial 
neoplasia were excluded from the study. Demographic and 
clinical characteristics of patients with and without prostate 
adenocarcinoma were compared with the use of statistical 
t-test.
This study was conducted in accordance with the Dec-
laration of Helsinki. The local medical ethical committee 
approved the study.
TRUS-guided, systematic, sextant, six-core biopsies with 
two additional biopsies from transition zone were done using 
a biopsy gun (Promag 1, MD Tech, Gainesville, FL) with an 
18-gauge biopsy needle (2.2 Biopsy Needle, MD Tech).13 The 
histological criteria for PCa used were those of the World 
Health Organization.13,14 Cancers were graded according to 
the Gleason grading system.15
Table 2 Characteristics of group A and group B
Characteristic Group A Group B
PsA, ng/mL 4–10 10–20
Mean age, years 64.38 68.5
number of cases (%) 226 (65.3%) 120 (34.7%)
Abbreviation: PSA, prostate-specific antigen.
Table 1 Age distribution of eligible cases
Age, years n (%)
,55 39 (11.3%)
56–60 68 (19.7%)
61–70 136 (39.3%)
71–75 52 (15%)
.76 51 (14.7%)Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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statistical analysis
The statistical analysis of the collected data were performed 
using SPSS Statistics, version 16.0 (SPSS Inc, Chicago, IL) 
software.16 The values of continuous variables were dem-
onstrated as mean ± standard deviation. Comparisons of 
variables (age, prostate volume, PSA, and pathologic diag-
nosis) were done with the t-test. P-values less than 0.05 were 
considered significant.
Results
The overall final pathologic diagnosis was prostate 
  adenocarcinoma in 193 cases (56%), BPH in 80 cases (23%), 
and   prostatitis – subacute or chronic – in 73 cases (21%). 
The group specific pathologic diagnosis was as   follows: for 
group A, prostate adenocarcinoma in 115 cases (51%), BPH 
in 59 cases (26%), and prostatitis – subacute or chronic – in 
52 cases (23%) (Table 3); for group B,   prostate adenocar-
cinoma in 78 cases (65%), BPH in 21 cases (17.5%), and 
prostatitis – subacute or chronic – in 21 cases (17.5%) 
(Table 3).
The mean (and SD) for age of group A and group B 
were, 64.38 years (8.134) and 68.5 years (8.56), respectively 
(Table 3).
The mean (and SD) prostate volume for group A and 
group B were 55 cm3 (23.963) and 59.5 cm3 (32.702), 
respectively. The mean prostate volume for PCa cases was 
46.09 cm3. The mean prostate volume for prostatitis cases was 
64.67 cm3, with SD of 26.304. The mean prostate volume for 
BPH cases was 74.06 cm3, with SD of 33.51 (Table 4).
The mean PSA level for PCa was 10.02 ng/dL, with SD of 
4.37. The mean PSA level for prostatitis was 8.76 ng/dL, with 
SD of 3.72. The mean PSA level for BPH was 8.41 ng/dL, 
with SD of 3.56.
The mean (and SD) age for PCa, prostatitis, and BPH 
were 67.63 years (8.98), 62.34 years (6.83), and 64.58 years 
(7.52), respectively (Table 4).
The mean Gleason score for group A was 6.5 and for 
group B was 6.7 (P # 0.05).
The statistical relation between the PSA level and PCa 
was significant (P , 0.40).
ANOVA test was used for the determination of the 
relation between the age and PCa; and it was significant 
(P , 0.01). With this test, the relation between PCa and 
BPH was significant (P , 0.01). The relation between age 
and PSA was significant (P . 0.01). Based on our study, the 
positive predictive value for PCa in group A was 51% and 
for group B, 65%.
Age was correlated positively with tPSA in both the PCa 
group and the BPH group in all tPSA ranges (0.001). This 
means that in our cases, the proportion of males with PSA 
levels above the cutoff value increased with age.
The mean PSA value (range, SD) in all men with PCa 
was 10 ng/mL (4–20 ng/mL, 4.37), in those with BPH was 
8.4 ng/mL (4–20 ng/mL, 3.56), and in those with prostatitis 
was 8.7 ng/mL (4–20, 3.72) ng/mL (P , 0.001) (Table 4).
Discussion
The incidence of PCa in Iran is significantly less than those 
in developed countries, and similar to eastern Mediterranean 
regions.17 PCa is the most frequently reported malignancy in 
Iranian males after stomach cancer.18,19 Among genitourinary 
cancers, it is the second most common cancer after bladder 
cancer, with an incidence of 33.4%.20 The lowest recorded 
PCa rate is 0.4 per 100 000 in Ardabil, northwest Iran.13,21 
Iranian men are ethnically and racially different from most 
of Asian men,22 so the biochemical parameters of PCa should 
be different. In a study by Khezri et al,23 in a large Iranian 
healthy male population, the serum PSA concentration cor-
related directly with the subject’s age and prostatic volume. 
Based on this study, the age-related PSA cutoff point was 
2.61 ng/mL for 50–59 years, 3.59 ng/mL for 60–69 years, 
and 4.83 ng/mL for 70–79 years. The serum PSA levels and 
prostate volume are age- and race-dependent. For this reason, 
we chose the cutoff point of 4 ng/mL for prostate biopsy. 
In another study by Mehrabi et al, the PSA cutoff level in 
the males older than 69 years is 4.4 ng/mL.24
Table 4 The relations between the pathologic diagnoses, age, 
PsA, and prostate volume
Mean age  
(SD)a
Mean PSA  
(SD)b
Prostate   
volumec
PCa 67.6 (8.9) 10.02 (4.37) 46 cm3
BPh 64.5 (7.5) 8.4 (3.56) 74 cm3
Prostatitis 62.3 (6.8) 8.7 (3.72) 64.67 cm3
Notes: aP = 0.01; bP = 0.4; cP = 0.01.
Abbreviations:  BPh,  benign  prostate  hyperplasia;  PCa,  prostate  cancer;  PsA, 
prostate-specific antigen; SD, standard deviation.
Table 3 histopathology of biopsied cases
Group Mean  
age (SD)
N n (%)
PCa BPH Prostatitis
group A 64.4 (8.13) 226 115 (51%) 59 (26%) 52 (23%)
group B 68.5 (8.5) 120 78 (65%) 21 (17.5%)  21 (17.5%)
Abbreviations: BPh, benign prostate hyperplasia; PCa, prostate cancer; sD, standard 
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In our study, of 346 patients with serum PSA levels 
between 4 and 20 ng/mL, only 56% had pathologically 
diagnosed PCa, which is much lower than values used 
in Western countries. This can be explained by a widely 
different geographical prevalence of PCa.25 Amirrasouli et al25 
evaluated 332 Iranian men with serum tPSA levels of 
4–20 ng/mL. After TRUS prostate biopsy, they detected PCa 
in 15% of their patients. Incidence of PCa for serum tPSA 
level 10 ng/mL and serum tPSA level of 10.1–20.0 ng/mL 
was 6.7% and 39.5%, respectively. Catalona et al,26 found 
positive findings on prostate biopsy in less than 50% of the 
patients with PSA of 4–10 ng/mL.
Several studies showed an advantage of using PSAD 
compared with tPSA alone.11,12,27–30 Lam et al31 recommended 
a PSAD cutoff of 0.15 ng/mL for detection of PCa, which 
spared half of the patients from undergoing unnecessary 
biopsies. In spite of its value, we did not consider the role 
of PSAD in this study.
Although several studies showed that PSA screening 
had a beneficial effect, the results of the selected studies 
were inconsistent, and mass screening is not warranted.32,33 
Both PSA and DRE were not recommended for population-
based screening programs, but they could be conducted 
individually.32
Hua et al34 studied the prostate biopsy results in 295 
  Chinese cases with PSA levels $4 ng/mL; the positive detec-
tion rate of PCa was 19.7%. In our Iranian cases, the positive 
detection rate was 56%.
We observed, like Gohji et al,35 in the patients with PCa, 
the prostate volume was smaller, and the age was higher than 
in the patients with BPH or prostatitis.
In the Safarinejad study,13 the detection rate of PCa in 
Iranian males using PSA alone was reported at 3.5%, which 
reflects an increase in its incidence. In addition, Safarinejad 
detected 17.5% PCa in cases with PSA 4–10 ng/mL, and 
47.6% in cases with PSA 10–20 ng/mL.
Conclusion
Comparing our study results with others, we found that PSA 
alone can be used efficiently as a first and/or repeat test for 
PCa screening of Iranian males. In addition, we found that the 
chance of PCa increases with increasing age, lesser weight 
of prostate, and increased tPSA. There was no difference in 
the Gleason score in our two groups of different PSA levels 
(4–10 and 10–20 ng/mL).
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